Ukrainian pharmaceutical company Biopharma is preparing to launch the first phase of a modern plant for the production of pharmaceutical and immunobiological products in Zakarpattia region. The facility is scheduled to open in September 2026, Prime Minister Yuliia Svyrydenko said.
The new plant will become one of the largest facilities of its kind in Europe and will provide a full cycle of donor blood plasma processing directly in Ukraine. This is expected to significantly strengthen the country’s position in the production of high-tech pharmaceuticals and reduce its dependence on external markets.
The company plans to create around 150 jobs at the facility. Construction of the main production building has already been completed, and key equipment has been installed at the site.
The total investment in the first phase of the project amounts to €75 million, of which €67 million has already been invested. The project is part of the company’s strategy to expand production capacity and strengthen its export potential.
Biopharma already supplies its products to dozens of countries worldwide and plans to further expand its presence in the markets of Europe, the Middle East, and Latin America.
In addition to its manufacturing activities, the company is actively investing in the development of biological education in Ukraine. In particular, Biopharma has opened two specialized biology classes in Kyiv and has also established two BioSchools in Kyiv and Bila Tserkva. The company plans to launch another 25–30 similar educational projects, with the next ones expected to open in Uzhhorod, Lviv, and Dnipro.
Biopharma Plasma LLC specializes in the development and production of innovative medicines derived from human donor blood plasma. According to YouControl, the company’s ultimate beneficial owners are Kostiantyn Yefymenko and Vasyl Khmelnytskyi, who exercise indirect decisive control over the business.
